Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells

Clinical Cancer Research

Volumn 5, Issue 11, 1999, Pages 3704-3710

  Pustilnik, Terri B ^a   Estrella, Veronica ^a   Wiener, Jon R ^a   Mao, Muling ^a   Eder, Astrid ^a   Watt, Mary Anne V ^a   Bast Jr , Robert C ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSOPHOSPHATIDIC ACID; UROKINASE;

ARTICLE; ASCITES; CANCER CELL CULTURE; CANCER INVASION; CELL ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; METASTASIS; MITOGENESIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LUCIFERASES; LYSOPHOSPHOLIPIDS; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032712996     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Morrow, C. P., and Austin, J. P. Gynecologic Cancer Surgery, p. 627. Edinburgh, United Kingdom: Churchill Livingstone, Inc., 1996.
2. Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A., Holub, B. J., and Mills, G. B. Characterization of an ovarian cancer activation factor in ascites from ovarian cancer patients. Clin. Cancer Res., 1: 1223-1232, 1995.
3. Westermann, A. M., Havid, E., Postma, F. R., Beijnen, J. H., Dalesio, O., Moolenaar, W. H., and Rodenhuis, S. Malignant effusions contain lysophosphaditic acid (LPA)-like activity. Ann. Oncol., 9: 437-442, 1998.
4. Goetzl, E. J., and An, S. Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. FASEB J., 12: 1589-1598, 1998.
5. Jalink, K., Hordijk, P. L., and Moolenaar, W. H. Growth-factor like effects of lysophosphatidic acid, a novel mediator. Biochim. Biophys. Acta, 1198: 185-196, 1994.
6. Xu, Y., Fang, X., Casey, G., and Mills, G. B. Lysophospholipids activate ovarian and breast cancer cells. Biochem. J., 309: 933-940, 1995.
7. Imamura, F., Horai, T., Mukai, M., Shinkai, K., Sawada, M., and Akedo, H. Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem. Biophys. Res. Commun., 193: 497-503, 1993.
8. Duffy, M. J. Proteases as prognostic markers in cancer. Clin. Cancer Res., 2: 613-618, 1996.
9. Odekon, L. E., Sato, Y., and Rifkin, D. B. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell. Physiol., 150: 258-263, 1992.
10. Young, T. N., Rodriquez, G. C., Moser, T. L., Bast, R. C., Pizzo, S. V., and Stack, S. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am. J. Obstet. Gynecol., 170: 1285-1296, 1994.
11. Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Bontenbal, M., Janicke, F., and Klijn, J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res., 52: 6101-6105, 1992.
12. Boyd, D., Ziober, B., Chakrabarty, S., and Brattain, M. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res., 49: 816-820, 1989.
13. Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., Schmitt, M., Janicke, F., Holfer, H., and Graeff, H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55: 3958-3963, 1995.
14. Kuhn, W., Fache, L., Schmalfeldt, B., Dettmar, P., Schmitt, M., Janicke, F., and Graeff, H. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol., 55: 401-409, 1994.
15. Chambers, S. K., Gertz, R. E., Jr., Ivins, C. M., and Kacinski, B. M. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptors in ascites of patients with epithelial ovarian cancer. Cancer (Phila.), 75: 1627-1633, 1995.
16. Karlan, B. Y., Amin, W., Band, V., Zurawski, V. R., Jr., and Littlefield, B. A. Plasminogen activator secretion by established lines of human ovarian carcinoma cells in vitro. Gynecol. Oncol., 31: 103-112, 1988.
17. Moser, T. L., Young, T. N., Rodriquez, G. C., Pizzo, S. V., Bast, R. C., Jr., and Stack, M. S. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer, 50: 552-559, 1994.
18. Casslen, B., Gustavsson, B., and Astedt, B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumors. Eur. J. Cancer, 27: 1445-1448, 1991.
19. Auersperg, N., Maines-Bandiera, S. L., Dyck, H. G., and Kruk, P. A. Characterization of cultured human ovarian surface epithelial cells: phenotypic plasticity and premalignant changes. Lab. Investig., 71: 510-518, 1994.
20. Heussen, C., and Dowdle, E. B. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copyolymerized substrates. Anal. Biochem., 102: 196-202, 1980.
21. Schauer, U., Krolikowski, I., and Rieger, C. H. Detection of activated lymphocyte subsets by fluorescence and MTT staining. J. Immunol. Methods, 116: 221-227, 1989.
22. Wiener, J. R., Kerns, B. J., Harvey, E. L., Conaway, M. R., Iglehart, J. D., Berchuck, A., and Bast, R. C. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J. Natl. Cancer Inst., 86: 372-378, 1994.
23. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159, 1987.
24. Casslen, B., Bossmar, T., Lecander, I., and Astedt, B. Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancer. Eur. J. Cancer, 30A: 1302-1309, 1994.
25. Gleeson, N. C., Hill, B. J., Moscinski, L. C., Mark, J. E., Roberts, W. S., Hoffman, M. S., Fiorica, J. V., and Cavanagh, D. Urokinase plasminogen activator in ovarian cancer. Eur. J. Gynaecol. Oncol., 17: 110-113, 1996.
26. Duffy, M. J. Urokinase plasminogen activator and malignancy. Fibrinolysis, 7: 295-302, 1993.
27. Plow, E. F., Freany, D. E., Plescia, J., and Miles., L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol., 103: 2411-2420, 1986.
28. Birkedal-Hansen, H. Proteolytic remodeling of extracellular matrix. Curr. Opin. Cell Biol., 7: 728-735, 1995.
29. Xu, Y., Shen, Z., Wiper, D. W., Wu, M., Morton, R. E., Elson, P., Kennedy, A. W., Belinson, J., Markman, M., and Casey, G. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. J. Am. Med. Assoc., 280: 719-723, 1998.
30. Kobayashi, H., Fujie, M., Shinohara, H., Ohi, H., Sugimura, M., and Terao, T. Effects of urinary trypsin inhibitor on the invasion of reconstituted basement membranes by ovarian cancer cells. Int. J. Cancer, 57: 378-384, 1994.
31. Bandoh, K., Aoki, J., Hosono, H., Kobayashi, S., Kobayashi, T., Murakami-Murofushi, K., Tsujimoto, M., Arai, H., and Inoue, K. Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid. J. Biol. Chem., 274: 27776-27785, 1999.